Jerrold Sendrow Biography and Net Worth

Director of Virpax Pharmaceuticals

Mr. Jerrold Sendrow has been a Certified Financial Planner since 1986, and maintains an active practice. Mr. Sendrow also served as an outside Director on the Board of Directors of SCILEX Pharmaceuticals Inc. from 2014 to 2016. In addition, up through 2014, Mr. Sendrow has more than 35 years of experience as Chief Financial Officer and Director in companies with revenues in excess of $500 million. Jerry has led these companies through start-up, survival, turnaround and growth modes. Prior to that, Mr. Sendrow was an accountant in the audit departments of Touche Ross & Co. and Peat Marwick Mitchell & Co after returning from military service of two tours in the Vietnam conflict. Mr. Sendrow holds business degrees from Bernard Baruch College of the City University of New York and Adelphi University.

What is Jerrold Sendrow's net worth?: The estimated net worth of Jerrold Sendrow is at least $297.00 as of May 24th, 2022. Mr. Sendrow owns 900 shares of Virpax Pharmaceuticals stock worth more than $297 as of December 22nd. This net worth estimate does not reflect any other investments that Mr. Sendrow may own. Learn More about Jerrold Sendrow's net worth.
How do I contact Jerrold Sendrow?: The corporate mailing address for Mr. Sendrow and other Virpax Pharmaceuticals executives is 1055 Westlakes Drive Suite 300, Berwyn PA, 19312. Virpax Pharmaceuticals can also be reached via phone at 610-727-4597 and via email at [email protected]. Learn More on Jerrold Sendrow's contact information.
Has Jerrold Sendrow been buying or selling shares of Virpax Pharmaceuticals?: Jerrold Sendrow has not been actively trading shares of Virpax Pharmaceuticals within the last three months. Most recently, on Tuesday, May 24th, Jerrold Sendrow bought 450 shares of Virpax Pharmaceuticals stock. The stock was acquired at an average cost of $12.90 per share, with a total value of $5,805.00. Following the completion of the transaction, the director now directly owns 900 shares of the company's stock, valued at $11,610. Learn More on Jerrold Sendrow's trading history.
Who are Virpax Pharmaceuticals' active insiders?: Virpax Pharmaceuticals' insider roster includes Anthony Mack (CEO), and Jerrold Sendrow (Director). Learn More on Virpax Pharmaceuticals' active insiders.

Jerrold Sendrow Insider Trading History at Virpax Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/24/2022	Buy	450	$12.90	$5,805.00	900
11/22/2021	Buy	390	$39.20	$15,288.00

Jerrold Sendrow Buying and Selling Activity at Virpax Pharmaceuticals

Virpax Pharmaceuticals Company Overview

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Today's Range

Now: $0.33

$0.32

$0.37

50 Day Range

MA: $0.54

$0.30

$0.76

2 Week Range

Now: $0.33

$0.29

$5.48

Volume

970,033 shs

Average Volume

2,474,614 shs

Market Capitalization

$1.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.